These predisposing conditions, and inflammation in general, downregulate HO-1 expression and activity [67,74,100,101,102,103,104,105,106], further supporting that this compromised protection and diminished tolerance against inflammatory and oxidative stress promotes adverse clinical outcome in COVID-19 patients. The gene discussed is HMOX1; the disease is COVID-19.